Mr. Baltera has served as entrepreneur-in-residence at the venture capital firm of Frazier Healthcare Partners since January 2016 and is chief executive officer of Cirius Therapeutics. A seasoned pharmaceutical industry executive, Mr. Baltera acquired a wealth of business and product management experience during 17 years with biotech pioneer Amgen. Previously, from February 2015 until December 2015, Mr. Baltera served as CEO and a member of the board of directors of Laguna Pharmaceuticals, a privately-funded biotechnology company. In his recent role as CEO of Amira Pharmaceuticals, he led the company to acquisition by Bristol-Myers Squibb Company. He was instrumental in focusing Amira’s development efforts, strengthening and developing its pipeline and forging key collaborations with partners such as GlaxoSmithKline. Before becoming Amira’s CEO, Mr. Baltera held a number of senior management positions at Amgen, the last being vice president of corporate and contract manufacturing. He successfully used his collective experience to serve as team leader responsible for the approval of Kineret™ in rheumatoid arthritis, a highlight of his many accomplishments while at Amgen. Mr. Baltera currently serves on the board of directors of Xencor, Inc., a publicly-held biotechnology development company, and also serves on the board of directors of the following private companies: Panmira Pharmaceuticals, LLC, FLAP, LLC, and Ruga Corporation, as well as an industry group, the San Diego Venture Group. Mr. Baltera holds an M.B.A. from the Anderson School at the University of California, Los Angeles and earned a B.S. in Microbiology and an M.S. in Genetics from Pennsylvania State University.